The role of markers of inflammation in traumatic brain injury
- PMID: 23459929
- PMCID: PMC3586682
- DOI: 10.3389/fneur.2013.00018
The role of markers of inflammation in traumatic brain injury
Abstract
Within minutes of a traumatic impact, a robust inflammatory response is elicited in the injured brain. The complexity of this post-traumatic squeal involves a cellular component, comprising the activation of resident glial cells, microglia, and astrocytes, and the infiltration of blood leukocytes. The second component regards the secretion immune mediators, which can be divided into the following sub-groups: the archetypal pro-inflammatory cytokines (Interleukin-1, Tumor Necrosis Factor, Interleukin-6), the anti-inflammatory cytokines (IL-4, Interleukin-10, and TGF-beta), and the chemotactic cytokines or chemokines, which specifically drive the accumulation of parenchymal and peripheral immune cells in the injured brain region. Such mechanisms have been demonstrated in animal models, mostly in rodents, as well as in human brain. Whilst the humoral immune response is particularly pronounced in the acute phase following Traumatic brain injury (TBI), the activation of glial cells seems to be a rather prolonged effect lasting for several months. The complex interaction of cytokines and cell types installs a network of events, which subsequently intersect with adjacent pathological cascades including oxidative stress, excitotoxicity, or reparative events including angiogenesis, scarring, and neurogenesis. It is well accepted that neuroinflammation is responsible of beneficial and detrimental effects, contributing to secondary brain damage but also facilitating neurorepair. Although such mediators are clear markers of immune activation, to what extent cytokines can be defined as diagnostic factors reflecting brain injury or as predictors of long term outcome needs to be further substantiated. In clinical studies some groups reported a proportional cytokine production in either the cerebrospinal fluid or intraparenchymal tissue with initial brain damage, mortality, or poor outcome scores. However, the validity of cytokines as biomarkers is not broadly accepted. This review article will discuss the evidence from both clinical and laboratory studies exploring the validity of immune markers as a correlate to classification and outcome following TBI.
Keywords: biomarkers; chemokines; cytokines; inflammation; traumatic brain injury.
Similar articles
-
Suppression of acute proinflammatory cytokine and chemokine upregulation by post-injury administration of a novel small molecule improves long-term neurologic outcome in a mouse model of traumatic brain injury.J Neuroinflammation. 2008 Jun 30;5:28. doi: 10.1186/1742-2094-5-28. J Neuroinflammation. 2008. PMID: 18590543 Free PMC article.
-
A mathematical model of neuroinflammation in severe clinical traumatic brain injury.J Neuroinflammation. 2018 Dec 18;15(1):345. doi: 10.1186/s12974-018-1384-1. J Neuroinflammation. 2018. PMID: 30563537 Free PMC article.
-
Microglial-derived microparticles mediate neuroinflammation after traumatic brain injury.J Neuroinflammation. 2017 Mar 15;14(1):47. doi: 10.1186/s12974-017-0819-4. J Neuroinflammation. 2017. PMID: 28292310 Free PMC article.
-
The duality of the inflammatory response to traumatic brain injury.Mol Neurobiol. 2001 Aug-Dec;24(1-3):169-81. doi: 10.1385/MN:24:1-3:169. Mol Neurobiol. 2001. PMID: 11831551 Review.
-
Modulation of immune response by head injury.Injury. 2007 Dec;38(12):1392-400. doi: 10.1016/j.injury.2007.10.005. Epub 2007 Nov 28. Injury. 2007. PMID: 18048036 Review.
Cited by
-
Sleep fragmentation after traumatic brain injury impairs behavior and conveys long-lasting impacts on neuroinflammation.Brain Behav Immun Health. 2024 May 15;38:100797. doi: 10.1016/j.bbih.2024.100797. eCollection 2024 Jul. Brain Behav Immun Health. 2024. PMID: 38803369 Free PMC article.
-
Neutralization of Interleukin 1-beta is associated with preservation of thalamic capillaries after experimental traumatic brain injury.Front Neurol. 2024 Apr 26;15:1378203. doi: 10.3389/fneur.2024.1378203. eCollection 2024. Front Neurol. 2024. PMID: 38765267 Free PMC article.
-
Biofluid-based Biomarkers in Traumatic Brain Injury: A Narrative Review.Brain Neurorehabil. 2024 Mar 18;17(1):e8. doi: 10.12786/bn.2024.17.e8. eCollection 2024 Mar. Brain Neurorehabil. 2024. PMID: 38585027 Free PMC article. Review.
-
Neurotrauma-From Injury to Repair: Clinical Perspectives, Cellular Mechanisms and Promoting Regeneration of the Injured Brain and Spinal Cord.Biomedicines. 2024 Mar 13;12(3):643. doi: 10.3390/biomedicines12030643. Biomedicines. 2024. PMID: 38540256 Free PMC article. Review.
-
Connecting cellular mechanisms and extracellular vesicle cargo in traumatic brain injury.Neural Regen Res. 2024 Oct 1;19(10):2119-2131. doi: 10.4103/1673-5374.391329. Epub 2023 Dec 21. Neural Regen Res. 2024. PMID: 38488547 Free PMC article.
References
-
- Aderka D., Le J. M., Vilcek J. (1989). IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. J. Immunol. 143, 3517–3523 - PubMed
-
- Agay D., Andriollo-Sanchez M., Claeyssen R., Touvard L., Denis J., Roussel A. M., et al. (2008). Interleukin-6, TNF-alpha and interleukin-1 beta levels in blood and tissue in severely burned rats. Eur. Cytokine Netw. 19, 1–7 - PubMed
-
- Aloisi F., Care A., Borsellino G., Gallo P., Rosa S., Bassani A., et al. (1992). Production of hemolymphopoietic cytokines (IL-6, IL-8, colony-stimulating factors) by normal human astrocytes in response to IL-1 beta and tumor necrosis factor-alpha. J. Immunol. 149, 2358–2366 - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources